Loading clinical trials...
Loading clinical trials...
Does the Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?
Conditions
Interventions
Semaglutide Injectable Product
Placebo
Locations
1
Denmark
Psychiatric Center Copenhagen, Frederiksberg Hospital
Frederiksberg, Denmark
Start Date
June 13, 2023
Primary Completion Date
July 31, 2025
Completion Date
July 31, 2025
Last Updated
August 5, 2025
NCT06939088
NCT06265506
NCT06367348
NCT06247306
NCT06607562
NCT04014413
Lead Sponsor
Psychiatric Centre Rigshospitalet
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions